IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
04 3월 2024 - 10:01PM
Business Wire
The Company to host an earnings conference call
via webcast.
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an artificial intelligence-driven biotherapeutic
research and technology company, today announced that it will host
a conference call to discuss its quarterly results and recent
business highlights for third fiscal year 2024, on Thursday, March
14, 2024, at 10:30 am Eastern Time. The financial results will be
issued in a press release prior to the call.
ImmunoPrecise management will host the conference call followed
by a question-and-answer period.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to
discuss these results and provide a corporate update on Thursday,
January 14, 2024, at 10:30AM ET.
The conference call will be webcast live and available for
replay via a link provided in the Events section of the Company’s
IR pages at
https://ir.ipatherapeutics.com/events-and-presentations/default.aspx
***Participant Dial-In
Details***
Participants call one of the allocated
dial-in numbers (below) and advise the Operator of either the
Conference ID 9236374 or Conference Name.
North America Toll-Free: (888)
550-5658 North America Toll: (646)
960-0289 International Toll: +1(646)
960-0289
***Webcast Details***
Attendee URL:
For inclusion in your invitations to
shareholders and guests.
https://events.q4inc.com/attendee/157226149
Please call the conference telephone number five minutes prior
to the start time. An operator will register your name and
organization.
Anyone listening to the call is encouraged to read the company's
periodic reports available on the company’s profile at
www.sedarplus.com and www.sec.gov, including the discussion of risk
factors and historical results of operations and financial
condition in those reports.
ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modelling and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240304754427/en/
investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024